Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.
A scientist’s account of switching focus to tackle pressing problems, and researchers consider the best way to preserve eggs, in our weekly dip into Nature’s archive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results